Business Description
Anhui Heryi Pharmaceutical Co Ltd
ISIN : CNE100005W81
Compare
Compare
Traded in other countries / regions
430478.China IPO Date
2023-02-23Description
Anhui Heryi Pharmaceutical Co Ltd engages in research and development, production, and sales of advanced pharmaceutical intermediates, raw materials, and related products. The main product categories include anti-allergy, anti-thrombosis, anti-oxidation, gastric ulcer, anti-virus, antipyretic and analgesic, and ultraviolet absorbent.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 82.38 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 119.71 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 16.88 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.3 | |||||
| 3-Year EBITDA Growth Rate | -7.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.5 | |||||
| 3-Year FCF Growth Rate | -12.2 | |||||
| 3-Year Book Growth Rate | 13.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.25 | |||||
| 9-Day RSI | 39.44 | |||||
| 14-Day RSI | 42.51 | |||||
| 6-1 Month Momentum % | 73.68 | |||||
| 12-1 Month Momentum % | -10.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.91 | |||||
| Quick Ratio | 5.94 | |||||
| Cash Ratio | 5.03 | |||||
| Days Inventory | 204.76 | |||||
| Days Sales Outstanding | 30.47 | |||||
| Days Payable | 90.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.13 | |||||
| Dividend Payout Ratio | 0.42 | |||||
| Forward Dividend Yield % | 2.13 | |||||
| 5-Year Yield-on-Cost % | 2.12 | |||||
| 3-Year Average Share Buyback Ratio | -10.2 | |||||
| Shareholder Yield % | 1.84 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.17 | |||||
| Operating Margin % | 18.57 | |||||
| Net Margin % | 17.84 | |||||
| FCF Margin % | 10.52 | |||||
| ROE % | 9.9 | |||||
| ROA % | 8.65 | |||||
| ROIC % | 15.73 | |||||
| ROC (Joel Greenblatt) % | 24.56 | |||||
| ROCE % | 10.64 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.67 | |||||
| PE Ratio without NRI | 20.67 | |||||
| Shiller PE Ratio | 19.95 | |||||
| Price-to-Owner-Earnings | 37.37 | |||||
| PEG Ratio | 1.42 | |||||
| PS Ratio | 3.74 | |||||
| PB Ratio | 2.37 | |||||
| Price-to-Tangible-Book | 2.37 | |||||
| Price-to-Free-Cash-Flow | 45.46 | |||||
| Price-to-Operating-Cash-Flow | 27.75 | |||||
| EV-to-EBIT | 18.78 | |||||
| EV-to-EBITDA | 18.78 | |||||
| EV-to-Revenue | 3.71 | |||||
| EV-to-FCF | 35.24 | |||||
| Price-to-Projected-FCF | 1.88 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.01 | |||||
| Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 3.45 | |||||
| Price-to-Net-Cash | 6.08 | |||||
| Earnings Yield (Greenblatt) % | 5.32 | |||||
| FCF Yield % | 2.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anhui Heryi Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 256.552 | ||
| EPS (TTM) (Â¥) | 0.961 | ||
| Beta | 0 | ||
| Volatility % | 66.89 | ||
| 14-Day RSI | 42.51 | ||
| 14-Day ATR (Â¥) | 2.0853 | ||
| 20-Day SMA (Â¥) | 21.601 | ||
| 12-1 Month Momentum % | -10.28 | ||
| 52-Week Range (Â¥) | 11.11 - 29.48 | ||
| Shares Outstanding (Mil) | 56.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anhui Heryi Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anhui Heryi Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anhui Heryi Pharmaceutical Co Ltd Frequently Asked Questions
What is Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478)'s stock price today?
The current price of BJSE:430478 is ¥18.79. The 52 week high of BJSE:430478 is ¥29.48 and 52 week low is ¥11.11.
When is next earnings date of Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478)?
The next earnings date of Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478) is .
Does Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478) pay dividends? If so, how much?
The Dividend Yield %  of Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478) is 2.13% (As of Today), Highest Dividend Payout Ratio of Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478) was 0.42. The lowest was 0.24. And the median was 0.24. The  Forward Dividend Yield % of Anhui Heryi Pharmaceutical Co Ltd(BJSE:430478) is 2.13%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers